Nasopharyngeal Carcinoma

Oncology·MeSH: Nasopharyngeal Carcinoma

Prevalence

5.0 / 100K

8 drugs in development·6 companies·11 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
loqtorzi	Coherus Oncology, Inc. (CHRS)

Phase 3(1)

Drug	Company
Cabozantinib S-malate	Royalty Pharma plc (RPRX)

Phase 2(5)

Drug	Company
Cabozantinib S-malate	ENANTA PHARMACEUTICALS INC (ENTA)
Recombinant human tissue kallikrein	Merus N.V. (MRUS)
Relatlimab	ENANTA PHARMACEUTICALS INC (ENTA)
tqb2618	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
tqb2618 injection; penpulimab	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

Phase 1(1)

Drug	Company
nana-val	Viracta Therapeutics, Inc. (VIRX)

BioSniper tracks 8 drugs in development for Nasopharyngeal Carcinoma across 6 companies.

There are 11 clinical trials targeting Nasopharyngeal Carcinoma tracked by BioSniper.

The estimated prevalence of Nasopharyngeal Carcinoma is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.